Immune checkpoint inhibitors (ICIs) targeting PD-L1, such as nivolumab, have dramatically improved the treatment landscape for advanced non-small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.